Package Leaflet: Information for the User
Apicassa 2.5 mg Film-Coated Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Package Leaflet
This medicine contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps prevent the formation of blood clots by blocking Factor Xa, an important element in blood coagulation.
Apixaban is used in adults:
Do not take Apicassa:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting to take this medicine if you have any of these conditions:
This medicine will be used with caution in patients with signs of altered liver function
Be careful with this medicine
If you need to have surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a while. If you are not sure if a procedure may cause bleeding, talk to your doctor.
Children and adolescents
This medicine is not recommended for use in children and adolescents under 18 years of age.
Other medicines and Apicassa
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use other medicines.
Some medicines may increase the effects of apixaban, and some medicines may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of apixaban and increase the possibility of an unwanted hemorrhage:
The following medicines may reduce the ability of apixaban to prevent the formation of blood clots.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The effects of apixaban on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.
It is not known if apixaban is excreted in human milk. Ask your doctor or pharmacist before taking this medicine during breastfeeding. They will tell you whether to stop breastfeeding or whether to stop or not start taking this medicine.
Driving and using machines
Apixaban has no influence on the ability to drive or use machines.
Apicassa contains lactose (a type of sugar) and sodium.
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially, "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are in doubt, consult your doctor, pharmacist, or nurse again.
Dosage
Take the tablet with water. This medicine can be taken with or without food.
Try to take the tablets at the same time each day to achieve a better treatment effect.
If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take Apicassa. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions for crushing:
If necessary, your doctor may also administer the crushed Apicassa tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take Apicassa according to the following recommendations:
To prevent the formation of blood clots in hip or knee replacement surgery.
The recommended dose of Apicassa is one 2.5 mg tablet twice a day.
For example, take one tablet in the morning and one in the evening.
You should take the first tablet between 12 and 24 hours after surgery.
If you have had major hipsurgery, you will usually take the tablets for a period of 32 to 38 days.
If you have had major kneesurgery, you will usually take the tablets for a period of 10 to 14 days.
To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor.
The recommended dose of Apicassa is one 5 mg tablet twice a day.
The recommended dose is one 2.5 mg tablet twice a day if:
The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long you should continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose is two 5 mg tabletstwice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose is one 5 mg tablettwice a day, for example, one tablet in the morning and one in the evening.
To prevent blood clots from recurring after 6 months of treatment
The recommended dose is one 2.5 mg tablet twice a day, for example, one tablet in the morning and one in the evening.
Your doctor will tell you how long you should continue the treatment.
Your doctor may change your anticoagulant treatment as follows:
Stop taking Apicassa. Start treatment with anticoagulant medicines (e.g., heparin) at the time you would take the next Apicassa tablet.
Stop taking anticoagulant medicines. Start treatment with Apicassa at the time you would take the next dose of an anticoagulant medicine, and then continue as usual.
Stop taking the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking Apicassa.
If your doctor tells you to start taking a medicine that contains a Vitamin K antagonist, continue taking Apicassa for at least 2 days after your first dose of the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking Apicassa.
Patients undergoing cardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor indicates to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.
If you take more Apicassa than you should
Tell your doctor immediatelyif you have taken a dose higher than the prescribed dose of this medicine. Take the package of the medicine to your doctor, even if there are no tablets left.
If you take more apixaban than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse the anti-factor Xa activity may be necessary.
In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Apicassa
If you have doubts about what to do or if you forget to take more than one dose,ask your doctor, pharmacist, or nurse.
If you stop taking Apicassa
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be higher if you stop the treatment too soon.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. Apixaban can be administered for three different diseases. The known adverse effects and the frequency with which they occur may be different and are therefore indicated separately below. For these conditions, the most frequent adverse effect of this medicine is bleeding, which can endanger the patient's life and requires immediate medical attention.
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in hip or knee replacement surgeries.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Unknown Frequency (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Unknown Frequency (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to treat or prevent blood clots from recurring in the veins of the legs and in the blood vessels of the lungs.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Unknown Frequency (cannot be estimated from available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and on each blister after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines that you no longer need at the SIGRE collection point in the pharmacy or in any other Medicinal Waste Collection System. If in doubt, ask your pharmacist how to dispose of the packaging and medicines that you no longer need. This will help protect the environment.
Composition of Apicassa
See section 2 "Apicassa contains lactose (a type of sugar) and sodium".
Appearance of the Product and Package Contents
Yellow, round, biconvex film-coated tablets with "IU1" engraved on one side and the other side smooth.
Not all pack sizes may be marketed.
Patient Information Card: Information Management
Inside the Apicassa package, along with the leaflet, you will find a Patient Information Card or your doctor may give you a similar card.
This Patient Information Card includes useful information for you and will alert other doctors that you are being treated with Apicassa. You must keep this card with you at all times.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
Mylan Hungary Kft.
H-2900 Komárom
Mylan utca. 1
Hungary
or
Laboratori Fundació Dau
C/ C, 12-14 Pol. Ind. Zona Franca,
Barcelona, 08040, Spain
or
Pharmadox Healthcare Limited
KW20A Corradino Industrial, state,
Paola, PLA 3000, Malta
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
Date of the Last Revision of this Leaflet:April 2022
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)